Bourne J P, Geyer R, Berger M, Griffin B, Milstein J
Children's Hospital & Med Center, University of Washington, Seattle.
J Neurooncol. 1992 Nov;14(3):263-70. doi: 10.1007/BF00172602.
The clinical and therapeutic features of 20 patients with medulloblastoma treated at Children's Hospital and Medical Center, Seattle, from 1980 to 1987, were retrospectively analyzed with regard to prognosis. The overall actuarial 5-year survival rate was 63%, with 57% of patients free from recurrence at 5 years. Residual contrast enhancement on CT scans taken immediately postoperatively was associated with a significantly decreased 5-year recurrence-free survival rate; the 5-year recurrence-free survival rate was 100% for those patients without post-operative residual enhancement compared to 41% for those patients with residual enhancement. A high risk group of patients with residual contrast enhancement persisting one year following diagnosis was identified. No patient in this group survived without disease progression. Other factors, including sex, age at diagnosis, evidence of tumor dissemination, or extent of surgical resection as reported by the neurosurgeon, did not significantly influence prognosis.
对1980年至1987年在西雅图儿童医院和医疗中心接受治疗的20例髓母细胞瘤患者的临床和治疗特征进行了回顾性分析，以评估预后。总体精算5年生存率为63%，57%的患者在5年时无复发。术后立即进行的CT扫描上的残余对比增强与5年无复发生存率显著降低相关；术后无残余增强的患者5年无复发生存率为100%，而有残余增强的患者为41%。确定了一组诊断后一年仍存在残余对比增强的高危患者。该组中无一例患者在无疾病进展的情况下存活。其他因素，包括性别、诊断时年龄、肿瘤播散证据或神经外科医生报告的手术切除范围，对预后没有显著影响。
